Skip to search formSkip to main contentSkip to account menu

Canvaxin

National Institutes of Health

Related topics

Related topics

2 relations

Broader (2)

Cancer Vaccinespolyvalent melanoma cell vaccine

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2016
2016
Analysis of the in vivo proliferative capacity of a whole cell cancer vaccine.
Highly Cited
2009
Highly Cited
2009
Effect of Granulocyte/Macrophage Colony-Stimulating Factor on Vaccination with an Allogeneic Whole-Cell Melanoma Vaccine
Purpose: The availability of a variety of immune response modifiers creates an opportunity for improved efficacy of immunotherapy… 
Review
2005
Review
2005
Therapeutic vaccines for melanoma: current status.
Considerable clinical research is focused on improving systemic treatments for melanoma. Unfortunately, the disease is generally… 
2005
2005
Somatic gene mutations predict outcome of patients receiving adjuvant active specific immunotherapy after resection of stage IV melanoma
7522 Background: Cyoreductive surgery plus adjuvant active specific immunotherapy can improve prognosis in stage IV melanoma, if… 
2005
2005
Immunomodulation of responses to active immunization with a polyvalent immunotherapeutic: cyclophosphamide, H2 blockade, IL-2/IFNα and GM-CSF
2564 Background: Strong humoral and cellular immune responses in patients with melanoma receiving a specific active… 
2005
2005
Invasive melanoma patients treated with Canvaxin specific active immunotherapy show serconversion for both IgG and IgM antibody responses to numerous protein and glycolipid tumor antigens
2574 Background: Although few nonsurgical treatment options offer significant benefit for patients with high-risk melanoma… 
2004
2004
Technology evaluation: Canvaxin, John Wayne Cancer Institute/CancerVax.
  • S. Motl
  • Current opinion in molecular therapeutics (Print)
  • 2004
  • Corpus ID: 20197131
CancerVax and the John Wayne Cancer Institute are co-developing Biotechnology Tumor antigen Canvaxin, a vaccine containing over… 
2004
2004
Immune response to postsurgical adjuvant active immunotherapy with Canvaxin polyvalent cancer vaccine: correlations with clinical course of patients with metastatic melanoma.
The efficacy of cytoreductive surgery for metastatic melanoma depends in part on the patient's immune response, which can be… 
2004
2004
CD4 Help and Tumor Immunity: Beyond the Activation of Cytotoxic T Lymphocytes
CD4 T helper (Th) cells have been found to exist in three or more groups.1 Th1 cells preferentially stimulate cell-mediated… 
2003
2003
Humoral immune response to a therapeutic polyvalent cancer vaccine after complete resection of thick primary melanoma and sentinel lymphadenectomy.
PURPOSE A therapeutic polyvalent cancer vaccine (Canvaxin vaccine; CancerVax Corp, Carlsbad, CA) induces antibodies to a… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)